Odyssey Therapeutics, Inc. ODTX
—
20.51
0.58
2.91%
as of 25 Sep
- Market cap
- $957.8M
- P/E
- 0.0×
Follow ODTX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+1 more quarter Free account |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (2.26) | |
P/B ratio |
— | — | — | 0.00 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | 0.00 | |
EV/FCF |
— | — | — | 0.00 | |
Quick Ratio |
10.98 | 7.91 | 6.85 | — | |
Current Ratio |
11.36 | 8.33 | 7.20 | — | |
Net Debt/EBITDA |
5.71 | 4.55 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | — | — | — | |
Operating CF/Net income |
0.65 | 1.07 | — | 0.83 | |
Capex/Depreciation |
0.09 | (0.13) | — | 0.04 | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 3,151.93% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 1,378.42% | |
Intangible Assets out of Total Assets |
0.03 | 0.06 | 0.05 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 385.61% | |
Graham Net Nets |
— | — | — | 1.46 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (413.84%) | |
Free Cash Flow Yield |
— | — | — | 0.00% | |
Revenue per Share |
0.00 | 0.00 | — | 0.69 | |
Operating CF per Share |
(1.14) | (7.26) | — | (24.55) | |
Capex per Share |
0.00 | (0.03) | — | 0.04 | |
Free Cash Flow per Share |
(1.14) | (7.28) | — | (24.51) | |
Cash per Share |
10.26 | 31.07 | 0.00 | 0.00 | |
Shareholders Equity per Share |
13.91 | 31.80 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
13.91 | 31.80 | 0.00 | 0.00 | |
Free Cash Flow |
(34.41) | (41.18) | — | (34.21) | |
Working Capital |
293.17 | 162.89 | 164.18 | — | |
Capital Expenditures |
0.10 | (0.15) | — | 0.06 | |
Net Current Asset Value |
258.83 | 135.90 | 136.15 | 0.00 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | (0.06) | |
Net Profit Margin |
0.00% | 0.00% | — | (4,299.79%) | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Assets |
241.93 | — | — | — |
Columns are period end dates